Kiniksa Pharmaceuticals/$KNSA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Ticker
$KNSA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
315
ISIN
GB00BRXB0C07
Website
KNSA Metrics
BasicAdvanced
$2.1B
-
-$0.24
0.31
-
Price and volume
Market cap
$2.1B
Beta
0.31
52-week high
$30.69
52-week low
$17.82
Average daily volume
993K
Financial strength
Current ratio
3.659
Quick ratio
3.171
Long term debt to equity
1.666
Total debt to equity
2.167
Profitability
EBITDA (TTM)
-14.228
Gross margin (TTM)
54.38%
Net profit margin (TTM)
-3.52%
Operating margin (TTM)
-3.28%
Effective tax rate (TTM)
-168.58%
Revenue per employee (TTM)
$1,530,000
Management effectiveness
Return on assets (TTM)
-1.77%
Return on equity (TTM)
-3.81%
Valuation
Price to revenue (TTM)
4.328
Price to book
4.61
Price to tangible book (TTM)
4.77
Price to free cash flow (TTM)
47.613
Free cash flow yield (TTM)
2.10%
Free cash flow per share (TTM)
60.80%
Growth
Revenue change (TTM)
59.45%
Earnings per share change (TTM)
-291.46%
3-year revenue growth (CAGR)
89.48%
3-year earnings per share growth (CAGR)
-50.50%
What the Analysts think about KNSA
Analyst ratings (Buy, Hold, Sell) for Kiniksa Pharmaceuticals stock.
Bulls say / Bears say
ARCALYST achieved a 75% year-over-year growth in Q1 2025, with net product revenue reaching $137.8 million, leading Kiniksa to raise its 2025 revenue guidance to $590-$605 million. (stocktitan.net)
Kiniksa plans to initiate a Phase 2/3 clinical trial for KPL-387 in recurrent pericarditis in mid-2025, with Phase 2 data expected in the second half of 2026, potentially expanding its cardiovascular portfolio. (globenewswire.com)
Analysts have maintained a 'Buy' rating on Kiniksa, citing the expanding use and duration of ARCALYST treatment, which signals potential revenue growth. (markets.businessinsider.com)
Kiniksa reported a net loss of $43.2 million for the full year 2024, highlighting financial challenges despite revenue growth. (tipranks.com)
The company's Chief Medical Officer sold over $578,000 worth of shares in July 2024, which could be perceived negatively by investors. (investing.com)
Kiniksa discontinued the development of abiprubart in Sjögren’s disease, indicating potential setbacks in its pipeline diversification efforts. (tipranks.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
KNSA Financial Performance
Revenues and expenses
KNSA Earnings Performance
Company profitability
KNSA News
AllArticlesVideos
Heart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Is Strong Tailwind
Investors Business Daily·1 week ago
Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis
GlobeNewsWire·1 month ago
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kiniksa Pharmaceuticals stock?
Kiniksa Pharmaceuticals (KNSA) has a market cap of $2.1B as of July 12, 2025.
What is the P/E ratio for Kiniksa Pharmaceuticals stock?
The price to earnings (P/E) ratio for Kiniksa Pharmaceuticals (KNSA) stock is 0 as of July 12, 2025.
Does Kiniksa Pharmaceuticals stock pay dividends?
No, Kiniksa Pharmaceuticals (KNSA) stock does not pay dividends to its shareholders as of July 12, 2025.
When is the next Kiniksa Pharmaceuticals dividend payment date?
Kiniksa Pharmaceuticals (KNSA) stock does not pay dividends to its shareholders.
What is the beta indicator for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals (KNSA) has a beta rating of 0.31. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.